Informations générales (source: ClinicalTrials.gov)
Early Assessment of Anti-Angiogenic Treatment Efficacy in Advanced Renal Cancer by Using Contrast-Enhanced Sonography
Interventional
N/A
National Cancer Institute, France (Voir sur ClinicalTrials)
décembre 2007
29 juin 2024
RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure
a patient's response to treatment with drugs such as sunitinib malate, sorafenib
tosylate, or bevacizumab, and allow doctors to plan better treatment.
PURPOSE: This clinical trial is studying ultrasonography in assessing antiangiogenic
treatment in patients with advanced kidney cancer.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Hospitalier Universitaire Bretonneau de Tours - 37044 - Tours - France | Contact Person | Contact (sur clinicalTrials) | |||
Critères
Tous
DISEASE CHARACTERISTICS:
- Diagnosis of advanced renal cancer
- Planning to receive antiangiogenic treatment
- Detection of a target hepatic metastasis that is visible, located, and sized with
conventional sonography and CT scan and/or MRI
PATIENT CHARACTERISTICS:
- No active cardiac disease
- No severe arterial hypertension
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Diagnosis of advanced renal cancer
- Planning to receive antiangiogenic treatment
- Detection of a target hepatic metastasis that is visible, located, and sized with
conventional sonography and CT scan and/or MRI
PATIENT CHARACTERISTICS:
- No active cardiac disease
- No severe arterial hypertension
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics